Tepotinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Tepotinib production plant. It encompasses all critical aspects necessary for Tepotinib production, including the cost of Tepotinib production, Tepotinib plant cost, Tepotinib production costs, and the overall Tepotinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tepotinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tepotinib belongs to a class of targeted cancer therapies known as selective MET tyrosine kinase inhibitors. It targets and shuts down a problematic MET protein found on certain cancer cells, which normally sends out signals telling the tumour to keep growing fast. By blocking this protein, the medicine starves the cancer of those dangerous instructions without harming most healthy cells.

It is prescribed for adults battling advanced non-small cell lung cancer. It is taken as one 500 mg tablet daily until the cancer worsens or side effects become too much, making it convenient for long-term use. It is also utilised in MET-driven problems like amplified stomach or liver cancers and childhood neuroblastoma.

The market for Tepotinib is driven by its usage in precision oncology progress. Its ability to target MET exon 14 skipping mutations in NSCLC patients contributes to its market growth. The rise in biomarker testing and label growth to frontline therapy across the US, Europe, Japan, and China approvals fuels its market.

Its convenient once-daily oral dosing is preferred over capmatinib, and broader NSCLC therapeutic expansions lead to better applications. The industrial Tepotinib procurement is affected by elevated pricing because of complex synthesis. Also, payer analysis of value versus competitors, single-source supply from Merck KGaA and Eli Lilly GMP partners, along with mandatory companion diagnostics, impacts its sourcing strategies.

Raw Material for Tepotinib Production

According to the Tepotinib production plant project report, the key raw materials used in the production of Tepotinib include Acetylbenzonitrile, Glyoxylic Acid, Hydrazine Hydrate, and Aryl Boronate.

Production Process of Tepotinib

The extensive Tepotinib production cost report consists of the following major industrial production process:

1. From Acetylbenzonitrile: The Tepotinib synthesis starts with acetylbenzonitrile reacting with glyoxylic acid in acetic acid. This is followed by treatment with hydrazine hydrate and additional acetic acid to form arene TEPT-003. Selective Suzuki cross-coupling of aryl boronate with aryl iodide yields a biaryl intermediate. The bromide of intermediate is converted into pinacol boronate, then to phenol using sodium perborate tetrahydrate. The phenol undergoes Mitsunobu reaction to form piperidine intermediate, followed by Boc deprotection with formic acid to give  Tepotinib derivative as the final product.

Tepotinib is a selective MET kinase inhibitor with a molecular formula of C29H28N6O2 and a molecular weight of 492.58 g/mol. It appears as a white to off-white crystalline powder with a pKa value of 9.5 (basic) and a logP value of 4 (lipophilic). It is soluble in DMSO but shows less solubility in water and ethanol. It has a boiling point of around 626 degree Celsius and a density of 1.25 g/cm³. It is stored at −20 degree Celsius as a solid and has 72% of oral bioavailability. It has a clearance of 23.8 L/h and a half-life of 32 h, with 98% plasma protein binding independent of concentration.